Mimi Flensburg, DVM, PhD, is Chief Clinical Officer of RSPR Pharma AB. She has more than 15 years’ experience working with clinical development of drug candidates for pharmaceutical companies. Prior to her current position, Mimi headed the Clinical Development Department at the Danish Biotech Company Symphogen. She also brings experience from Genmab, where she was the Clinical Lead for the program which brought Azerra (ofatumumab) from Phase I to FDA approval in 5 years. Mimi gained her scientific education as Doctor of Veterinary Medicine and PhD in epidemiology from the University of Copenhagen.
epidemiology